Lumida
/ADPT
⌘K
Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

ADPT
$26.25USD+2.74%+0.70 today

MARKET CAP

4.2B

P/E (TTM)

FWD P/E

DAY RANGE

$25 – $26

52W RANGE

$12
$26

AI Summary

Stalk
StalkMedium

ADPT remains in a clear Stage 2 advance backed by rising long- and medium-term trends, with higher highs and higher lows confirming sustained demand. Short-term momentum is positive but overbought, so under a momentum-oriented approach we will defer buying until a shallow pullback into the 9/20EMA region shows absorption and acceptance. Patience is warranted to engage on a constructive retracement rather than chasing extended highs.

  • Q2 2026 revenue reached $71.6M, up 30% YoY, led by a 49% MRD surge
  • Adjusted EBITDA jumped to $9.1M from $1.9M YoY, boosting operating margins
  • Net loss of $39.9M in Q2 intensifies cash-burn and funding risks
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$154.3M$185.3M$170.3M$179.0M$277.0M
YoY %+56.9%+20.1%-8.1%+5.1%+54.8%
P / Sales25.5x6.0x4.0x4.9x8.9x
EV / Sales26.7x7.6x5.7x6.5x9.7x
Gross Profit, Adj.$105.0M$127.4M$94.7M$106.9M$205.6M
YoY %+38.5%+21.3%-25.6%+12.8%+92.4%
Margin %68.1%68.7%55.6%59.7%74.2%
EV / Gross Profit39.2x11.1x10.3x11.0x13.0x
EBITDA, Adj.$-195.0M$-179.3M$-179.4M$-136.1M$-39.3M
YoY %-35.1%+8.1%-0.1%+24.1%+71.1%
Margin %-126.3%-96.7%-105.3%-76.0%-14.2%
EV / EBITDA-21.1x-7.9x-5.4x-8.6x-68.2x
EBIT$-209.0M$-200.2M$-227.0M$-162.5M$-57.1M
YoY %-36.7%+4.2%-13.4%+28.4%+64.9%
Margin %-135.4%-108.0%-133.3%-90.8%-20.6%
EV / EBIT-19.7x-7.1x-4.3x-7.2x-46.9x
Net Income$-207.3M$-200.2M$-225.3M$-159.5M$-59.5M
YoY %-41.8%+3.4%-12.5%+29.2%+62.7%
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (GAAP)-$1.48-$1.40-$1.56-$1.08-$0.39
YoY %-33.3%+5.4%-11.4%+30.8%+63.9%